FDA committee to discuss Bayer's riociguat

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Aug. 6 to discuss an NDA from Bayer AG (Xetra:BAYN) for Adempas riociguat to treat pulmonary arterial hypertension (PAH) and chroni...